Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 26
- Registration Number
- NCT00535353
- Locations
- 🇨🇦
Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT00524186
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00522665
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
- Conditions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 35
- Registration Number
- NCT00513266
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland
🇨🇭Kantonspital Aarau, Chur, Switzerland
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00509860
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Second-Line Irinotecan vs. ILF for AGC
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2007-08-01
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00509964
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 26
- Registration Number
- NCT00509353
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT00507091
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
- Conditions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2007-07-25
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 100
- Registration Number
- NCT00507143
- Locations
- 🇰🇷
National Cancer Center Korea, Goyang, Gyeonggi, Korea, Republic of
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00499369
- Locations
- 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.